 Biocept Inc NASDAQ:BIOC announced Tuesday that its Target Selector molecular assay kit detected mutations in up to 50 of tissue biopsy specimens from non-small cell lung cancer patients that were deemed quantity not sufficient QNS by traditional testing methods in a recent study. The company plans to present its findings at the virtual Molecular Med Tri-Con Virtual Conference on February 16-18 this week. 